このエントリーをはてなブックマークに追加
ID 63200
フルテキストURL
fulltext.pdf 4.01 MB
著者
Nagasaki, Joji Chiba Cancer Center, Research Institute
Inozume, Takashi Chiba Cancer Center, Research Institute
Sax, Nicolas KOTAI Biotechnologies, Inc.
Ariyasu, Ryo Division of Cancer Immunology, National Cancer Center, Research Institute, Exploratory Oncology Research and Clinical Trial Center (EPOC)
Ishikawa, Masakazu KOTAI Biotechnologies, Inc.
Yamashita, Kazuo KOTAI Biotechnologies, Inc.
Kawazu, Masahito Division of Cellular Signaling, National Cancer Center, Research Institute
Ueno, Toshihide Division of Cellular Signaling, National Cancer Center, Research Institute
Irie, Takuma Division of Cancer Immunology, National Cancer Center, Research Institute, Exploratory Oncology Research and Clinical Trial Center (EPOC)
Tanji, Etsuko Chiba Cancer Center, Research Institute
Morinaga, Takao Chiba Cancer Center, Research Institute
Honobe, Akiko Department of Dermatology, University of Yamanashi
Ohnuma, Takehiro Department of Dermatology, University of Yamanashi
Yoshino, Mitsuru Department of Thoracic Surgery, Chiba Cancer Center
Iwata, Takekazu Department of Thoracic Surgery, Chiba Cancer Center
Kawase, Katsushige Chiba Cancer Center, Research Institute
Sasaki, Keita Department of Head and Neck Surgery, Chiba Cancer Center
Hanazawa, Toyoyuki Department of Otolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine
Kochin, Vitaly Department of Immunology, Nagoya University Graduate School of Medicine
Kawamura, Tatsuyoshi Department of Dermatology, University of Yamanashi
Matsue, Hiroyuki Department of Dermatology, Chiba University Graduate School of Medicine
Hino, Masayuki Department of Hematology, Graduate School of Medicine, Osaka City University
Mano, Hiroyuki Division of Cellular Signaling, National Cancer Center, Research Institute
Suzuki, Yutaka Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
Nishikawa, Hiroyoshi Division of Cancer Immunology, National Cancer Center, Research Institute, Exploratory Oncology Research and Clinical Trial Center (EPOC)
Togashi, Yosuke Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
PD-1 blockade exerts clinical efficacy against various types of cancer by reinvigorating T cells that directly attack tumor cells (tumor-specific T cells) in the tumor microenvironment (TME), and tumor-infiltrating lymphocytes (TILs) also comprise nonspecific bystander T cells. Here, using single-cell sequencing, we show that TILs include skewed T cell clonotypes, which are characterized by exhaustion (T-ex) or nonexhaustion signatures (Tnon-ex). Among skewed clonotypes, those in the T-ex, but not those in the Tnon-ex, cluster respond to autologous tumor cell lines. After PD-1 blockade, non-preexisting tumor-specific clonotypes in the T-ex cluster appear in the TME. Tumor-draining lymph nodes (TDLNs) without metastasis harbor a considerable number of such clonotypes, whereas these clonotypes are rarely detected in peripheral blood. We propose that tumor-infiltrating skewed T cell clonotypes with an exhausted phenotype directly attack tumor cells and that PD-1 blockade can promote infiltration of such T-ex clonotypes, mainly from TDLNs.
発行日
2022-02-01
出版物タイトル
Cell Reports
38巻
5号
出版者
Cell Press
開始ページ
110331
ISSN
2211-1247
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2022 The Author(s).
論文のバージョン
publisher
PubMed ID
NAID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1016/j.celrep.2022.110331
ライセンス
http://creativecommons.org/licenses/by/4.0/